Home  |  Contact

UniProtKB/Swiss-Prot P21333: Variant p.Ala1188Thr

Filamin-A
Gene: FLNA
Variant information

Variant position:  1188
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  LP/P [Disclaimer]
The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change:  From Alanine (A) to Threonine (T) at position 1188 (A1188T, p.Ala1188Thr).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from small size and hydrophobic (A) to medium size and polar (T)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  0
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In MNS; does not inhibit interaction with MIS18BP1.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  1188
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  2647
The length of the canonical sequence.

Location on the sequence:   PGLERATAGEVGQFQVDCSS  A GSAELTIEICSEAGLPAEVY
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         PGLERATAGEVGQFQVDCSSAGSAELTIEICSEAGLPAEVY

Mouse                         PGLERATAGEVGQFQVDCSSAGSAELTIEICSEAGLPAEVY

Drosophila                    -----------------------------------------

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 2 – 2647 Filamin-A
Repeat 1155 – 1249 Filamin 10


Literature citations

Identification of novel nuclear protein interactions with the N-terminal part of filamin A.
Qiu H.; Nomiyama R.; Moriguchi K.; Fukada T.; Sugimoto K.;
Biosci. Biotechnol. Biochem. 75:145-147(2011)
Cited for: INTERACTION WITH TAF1B AND MIS18BP1; CHARACTERIZATION OF VARIANTS ALA-1159; THR-1188 AND LEU-1199;

Localized mutations in the gene encoding the cytoskeletal protein filamin A cause diverse malformations in humans.
Robertson S.P.; Twigg S.R.F.; Sutherland-Smith A.J.; Biancalana V.; Gorlin R.J.; Horn D.; Kenwrick S.J.; Kim C.A.; Morava E.; Newbury-Ecob R.; Oerstavik K.H.; Quarrell O.W.J.; Schwartz C.E.; Shears D.J.; Suri M.; Kendrick-Jones J.; Wilkie A.O.M.;
Nat. Genet. 33:487-491(2003)
Cited for: VARIANTS OPD1 PHE-172; TRP-196 AND LEU-207; VARIANTS OPD2 PRO-170; GLY-196; SER-200; LYS-254; PRO-273; LYS-555 AND PHE-1645; VARIANTS FMD1 ALA-1159; LEU-1186 AND ILE-1620 DEL; VARIANTS MNS GLU-1184; THR-1188 AND LEU-1199; VARIANTS MET-429 AND THR-1764;

Otopalatodigital spectrum disorders: refinement of the phenotypic and mutational spectrum.
Moutton S.; Fergelot P.; Naudion S.; Cordier M.P.; Sole G.; Guerineau E.; Hubert C.; Rooryck C.; Vuillaume M.L.; Houcinat N.; Deforges J.; Bouron J.; Deves S.; Le Merrer M.; David A.; Genevieve D.; Giuliano F.; Journel H.; Megarbane A.; Faivre L.; Chassaing N.; Francannet C.; Sarrazin E.; Stattin E.L.; Vigneron J.; Leclair D.; Abadie C.; Sarda P.; Baumann C.; Delrue M.A.; Arveiler B.; Lacombe D.; Goizet C.; Coupry I.;
J. Hum. Genet. 61:693-699(2016)
Cited for: VARIANTS OPD2 SER-187 AND GLY-196; VARIANTS OPD1 LEU-207; THR-267; ASP-804 AND HIS-2391; VARIANTS FMD1 VAL-1142; LEU-1186 AND ARG-1840; VARIANTS MNS LEU-1163 AND THR-1188;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.